AKAP4 is a circulating biomarker for non-small cell lung cancer

• Published in: Oncotarget Vol. 6; no. 19; pp. 17637 - 17647
• Main Authors: Gumireddy, Kiranmai, Li, Anping, Chang, David H, Liu, Qin, Kossenkov, Andrew V, Yan, Jinchun, Korst, Robert J, Nam, Brian T, Xu, Hua, Zhang, Lin, Ganepola, Ganepola A P, Showe, Louise C, Huang, Qihong
• Format: Journal Article
• Language: English
• Published: United States Impact Journals LLC 10.07.2015
• Subjects: A Kinase Anchor Proteins - blood; Adult; Aged; Aged, 80 and over; Area Under Curve; Biomarkers, Tumor - blood; Carcinoma, Non-Small-Cell Lung - blood; Female; Humans; Lung Neoplasms - blood; Male; Middle Aged; Polymerase Chain Reaction; Research Paper; ROC Curve; Sensitivity and Specificity; circulating biomarker; cancer
• ISSN: 1949-2553; 1949-2553
• DOI: 10.18632/oncotarget.3946

Cancer testis antigens (CTAs) are widely expressed in tumor tissues, circulating tumor cells (CTCs) and in cancer derived exosomes that are frequently engulfed by lymphoid cells. To determine whether tumor derived CTA mRNAs could be detected in RNA from purified peripheral blood mononuclear cells (PBMC) of non-small cell lung cancer (NSCLC) patients, we assayed for the expression of 116 CTAs in PBMC RNA in a discovery set and identified AKAP4 as a potential NSCLC biomarker. We validated AKAP4 as a highly accurate biomarker in a cohort of 264 NSCLCs and 135 controls from 2 different sites including a subset of controls with high risk lung nodules. When all (264) lung cancers were compared with all (135) controls the area under the ROC curve (AUC) was 0.9714. When 136 stage I NSCLC lung cancers are compared with all controls the AUC is 0.9795 and when all lung cancer patients were compared to 27 controls with histologically confirmed benign lung nodules, a comparison of significant clinical importance, the AUC was 0.9825. AKAP4 expression increases significantly with tumor stage, but independent of age, gender, smoking history or cancer subtype. Follow-up studies in a small number of resected NSCLC patients revealed a decrease of AKAP4 expression post-surgical resection that remained low in patients in remission and increased with tumor recurrence. AKAP4 is a highly accurate biomarker for the detection of early stage lung cancer.